A cikin 'yan shekarun nan, tasirin masu hana kariya daga bincike kan cutar lymphoma na Hodgkin (HL) abin birgewa ne, amma har yanzu ana bukatar shawo kan cutar sosai. Shugaban Kungiyar Lymphoma na Mayo Clinic Ansell ya ce muna koyo daga ilmin kimiyyar lymphoma na Hodgkin kuma muna samar da karin dama don maganin lymphoma a nan gaba.
Muna magana game da tasirin toshewar PD-L1 a cikin HL, neman mafita mai zurfi, madadin hanyoyin haɗin magunguna waɗanda ke samun ci gaba, da yuwuwar hanyoyin ganowa nan gaba.
Ansell ya kawo karar wani mai haƙuri da HL. Ya kira shi dare daya ya sanar da shi cewa yana amfani da maganin nivolumab (Opdivo) yana da tasiri. Baya ga sauran cututtukan, mai haƙuri kuma ya faɗaɗa ƙwayoyin lymph kuma ba ya da sauran ƙwayoyin hannu. Tabbas, ya zama cewa HL dinsa yana samun sauki, amma bayan shekaru 2 na jinya, bai ɓace gaba ɗaya ba.
A matsayinsa na likitan rigakafi, Ansell ya ce ya yi matukar damuwa. A bayyane yake, kodayake maganin ya yi tasiri, ƙwayoyin rigakafi ba su nuna isasshen ƙwaƙwalwar ajiya. Ansell ya sami wani abin damuwa shine da alama cewa dole ne a kula da marassa lafiya ta wannan hanyar tsawon rayuwarsu.
Don sake nazarin shaidun nivolumab a matsayin magani na dubawa, lokaci guda hannu II CheckMate 205 ya sake komawa / gwajin gwajin Hodgkin lymphoma (cHL) na yau da kullun, wanda ya tabbatar da yawan amsawar (ORR) bayan bin hanyar mediya na watanni 18) 69%, matsakaiciyar lokacin amsar watanni 16.6 ne, kuma rashin samun ci gaban tsakani ya kasance watanni 14.7.
Binciken KEYNOTE-087 guda-hannu na II na pembrolizumab (Keytruda) don wannan cuta, wanda ORR na miyagun ƙwayoyi ya kasance 69.0%, kuma cikakkiyar adadin gafara (CR) shine 22.4%, marasa lafiya 31 sun amsa ≥ 6 watanni.
Binciken Phase I JAVELIN ya gwada avelumab (Bavencio) azaman mai zaɓin zaɓin PD-L1 a r / r HL. Ansell ya nuna cewa ORR na duk marasa lafiya 31 sun kasance 41.9% kuma amsawar da aka samu ta kasance 25.8%. Matsakaicin lokacin tsakiya shine watanni 1.5
An gwada wannan hanyar ta hanyar haɗawa da masu hana kariya daga abubuwan kariya nivolumab da ipilimumab (Yervoy). Nivolumab tana aiki azaman mai toshe PD-L1, ipilimumab yana ƙaddamar da tsarin rigakafi don rage tasirin CTLA-4. A cikin CheckMate 039, wannan ya haifar da ORR na 74% (n = 23) da ƙimar CR na 19% (n = 6). A halin yanzu, masu hana shingen kariya sun sami sakamako mai kyau wajen kula da cHL, amma har yanzu da sauran aiki a gaba, kuma ba za mu iya zama masu kyakkyawan fata ba.
